Astex and Otsuka Announce Results of the Phase 3 ASCERTAIN Study of the       Novel Oral Cedazuridine/Decitabine Fixed-Dose Combination (ASTX727) in       Patients with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic       Leukemia (CMML)